StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
ASARFI.BO$205.00+1.54%
Fair $205.00+0.0%

ASARFI.BO

Asarfi Hospital Ltd

Healthcare / Medical Care FacilitiesBSE

$205.00

+3.10 (+1.54%)

Fairly Valued+0.0%Fair Value $205.00Fund rank 25/100 · Data gapFallback financials|
SA 56/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-157.8M · quality 52.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

56/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · ASARFI.BOLocal privado en este navegador · Asarfi Hospital Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$4.0B

P/E

24.2x

↑

EV/EBITDA

11.8x

↓

ROE

17.1%

↑

Gross Margin

77.6%

↑

Debt/Equity

0.59

↑
52-Week Range$205
$109$257

TradingView lightweight chart

ASARFI.BO price, volumen y niveles de valoración

Último $205.00Periodo +98.1%
Fair value: $205.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+34.9%

FCF CAGR

—

FCF margin

0.1%

FCF / Net income

0.01x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.74B · net income $166.6M · FCF $1.9M

2023-FY → 2026-FY

Gross margin

77.6%+6.0% pts

Operating margin

13.7%-0.3% pts

Net margin

9.6%-1.7% pts

FCF margin

0.1%+31.5% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$1.74B$1.74B$1.22B$844.0M$707.0M
Net Income$166.6M$166.6M$105.8M$41.6M$80.2M
EBITDA$379.8M$379.8M$310.7M$173.1M$156.3M
EPS——5.372.314.07
Gross Margin77.6%77.6%77.1%73.3%71.7%
Operating Margin13.7%13.7%9.9%8.6%14.0%
Net Margin9.6%9.6%8.7%4.9%11.3%
Balance Sheet
Debt/Equity0.590.590.600.450.41
Current Ratio1.451.45———
Cash Flow
Free Cash Flow$1.9M$1.9M$-157.8M$-200.0M$-222.1M
Returns
ROE17.1%17.1%13.1%5.9%19.2%
Valuation
P/E24.1724.1715.0837.08—
EV/EBITDA11.7911.796.6510.74—
P/B4.134.131.972.20—
Growth & Yield
Revenue Growth42.5%42.5%44.3%19.4%—
EPS Growth——132.5%-43.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +73.7%

Total return

+73.7%

Start / end P/E

n/dx → n/dx

EPS bridge

5.37 → n/d

Residual

+73.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+73.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.